Healthcare

Assessing ReNerve requires looking beyond the broader healthcare opportunity and examining the commercial factors that influence medical-device companies. These include regulatory approvals, surgeon adoption, sales growth, margins and the company’s ability to fund operations while building its market presence.

Healius Limited (ASX:HLS) has disclosed a change in the size of a substantial shareholding, after First Sentier Group Limited and a number of related investment management entities lodged an updated Form 604 notice with the Australian Securities Exchange. The filing, dated 22 September 2026, …

Memphasys Limited (ASX:MEM) has revised its approach to bringing its Felix Sperm Separation System to the United States, after its board identified a route to regulatory clearance that could prove faster and less costly than the pathway previously under consideration. The ASX-listed reproductive health …

Microba Life Sciences Limited (ASX:MAP) has announced a leadership change at the top of the organisation, confirming that founding Chief Executive Officer Dr Luke Reid is currently on medical leave. In response, the Board has appointed Geoffrey Cockerill as Interim Chief Executive Officer, with …

In its preliminary final report signed 25 August 2026 for the financial year ended 30 June 2026, Star Combo Pharma reported revenues from ordinary activities of $23,573,050, a decrease of approximately $4.24 million from $27,811,548 in FY25. Profit from ordinary activities before tax was …

NeuroScientific reported a net loss of $4,693,164 for the year ended 30 June 2026, compared with a loss of $1,845,513 in FY25, as the company significantly increased R&DInvestmentfollowing the StemSmart™ platform acquisition. Total income of $629,398 increased materially on the prior year, primarily due …

Nexalis reported a net loss of $1,297,938 for the half-year ended 30 June 2026, compared with a loss of $854,332 in the prior corresponding period, primarily reflecting higher product development expenditure of $1,275,757 and director fees of $108,988. On the clinical side, the company …